Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Labcorp acquires assets of NMHS ambulatory outreach lab business

June 2025—Labcorp and North Mississippi Health Services announced that Labcorp has completed its acquisition of North Mississippi Health Services’ ambulatory outreach laboratory business and is now a referral laboratory for NMHS’ seven hospitals and clinic laboratories. In addition, Labcorp will open three patient service centers in Tupelo, West Point, and Amory by midyear to increase availability of laboratory services in North Mississippi.

FDA clears Liaison Plex Gram-negative blood culture assay

June 2025—Diasorin announced it has received FDA 510(k) clearance for the Liaison Plex Gram-negative blood culture assay, the second of the company’s three multiplex molecular panels for blood culture pathogen identification on the Liaison Plex. The assay is designed to identify 27 targets—19 Gram-negative bacteria and eight relevant resistance gene targets, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Acinetobacter species, Citrobacter species, Enterobacter species, and Proteus species. Results are available about two hours after a Gram stain.

Visby gets clearance, CLIA waiver for POC respiratory test

June 2025—Visby Medical announced it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its point-of-care Medical Respiratory Health test. The PCR test detects and differentiates between upper respiratory infections caused by influenza A and B and SARS-CoV-2 and provides results in less than 30 minutes.

Mayo Clinic, Kyan collaborate to expand access to cancer testing

June 2025—Mayo Clinic Laboratories and Kyan Technologies announced a collaboration to validate and provide Kyan’s Optim.AI across the United States. Optim.AI is an ex vivo drug sensitivity platform that combines small data AI and biological experiments. It provides insights into therapies for cancer patients and delivers efficiencies for cancer drug development. Mayo Clinic Labs will provide testing for physicians and researchers to support clinical and research decision-making for better treatment options.

Thermo Fisher launches centrifuges with GreenCool technology

June 2025—Thermo Fisher Scientific introduced new lines of floor-model centrifuges that feature natural refrigerant cooling systems compliant with European Union and U.S. Environmental Protection Agency fluorinated gas regulations. The Thermo Scientific Cryofuge, Bios, and Lynx centrifuges feature the company’s GreenCool technology, a next-generation natural refrigerant cooling system with a global warming potential of 1. Each model provides a reduction in energy consumption of up to 15 percent when compared with previous models.

StatLab adds new U.S. manufacturing capabilities

June 2025—StatLab Medical Products announced that it is vertically integrating the production of containers and lids at its facility in Arlington, Tex., where the company currently produces nearly 100 million prefills annually, and will begin blow-molding gallon bottles in Q2. StatLab says it will also absorb any tariff-related fees associated with products manufactured in its European facilities when selling directly to U.S. laboratories. These products include PiSmart cassette and slide printers, KT microscope slides, and KT coverglass.

IDT introduces xGen hybridization, wash kit v3

June 2025—Integrated DNA Technologies unveiled its xGen Hybridization and Wash version 3 kit. The kit features a high-throughput workflow that eliminates heated buffers and reduces hands-on time by 20 percent. The one-hour hybridization step delivers high-quality results and enables users to get from sample to sequencer in one day. The kit supports library inputs as low as 100 ng and pairs with xGen predesigned or custom Hyb panels and xGen Blocking Oligos.

Thermo Fisher launches NGS hybrid capture assay

June 2025—Thermo Fisher Scientific has introduced the One Lambda HybriType HLA Plus Typing Flex kit, a next-generation sequencing hybrid capture assay featuring a probe-based design that optimizes read balance and uniformity, potentially mitigating allele dropout. The assay is designed to provide flexibility in testing configuration and coverage, supporting human leukocyte antigen class I and II genotyping analysis across various sample types, including whole blood and buccal swabs. It has a turnaround time of less than 5.5 hours, and the hands-on time is less than 2.5 hours. Data for the assay are analyzed using the company’s Type­Stream Visual NGS analysis software. The kit is for research use only.

Dr. Jonathan Epstein joins Advanced Uropathology

June 2025—Advanced Uropathology, a division of Integrated Medical Professionals, announced that urologic pathologist Jonathan Epstein, MD, has joined its team. Physicians, hospitals, and laboratories can now refer specimens directly to Dr. Epstein, who will provide second opinions and expert interpretations of complex urologic pathology cases.

MARKETPLACE

TRENDING